Patents by Inventor Ethan Menahem Shevach

Ethan Menahem Shevach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1
    Publication number: 20240409640
    Abstract: Methods for regulating an immune response are described. More specifically, methods are described in which a compound is used to inhibit the interaction of an MHC class I molecule with a leukocyte immunoglobulin-like receptor B (LILRB) protein. Such inhibition results in activation of immune cells expressing the LILRB protein. Also described are uses of such methods for treating disease.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 12, 2024
    Inventors: Ethan Menahem Shevach, Abir Kumar Panda, David Harvey Margulies, Kannan Natarajan
  • GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF
    Publication number: 20100080809
    Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
    Type: Application
    Filed: August 28, 2009
    Publication date: April 1, 2010
    Applicants: Wyeth, The Government of the United States
    Inventors: Mary Collins, Ethan Menahem Shevach, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young, Michael Chapman Byrne, Padmalatha S. Reddy, Geoffrey Laurence Stephens, Beatriz M. Carreno
  • Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
    Patent number: 7618632
    Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: November 17, 2009
    Assignees: Wyeth, The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Mary Collins, Ethan Menahem Shevach, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young, Michael Chapman Byrne, Padmalatha S. Reddy, Geoffrey Laurence Stephens, Beatriz M. Carreno
  • CD25+ DIFFERENTIAL MARKERS AND USES THEREOF
    Publication number: 20080221016
    Abstract: The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25+ differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.
    Type: Application
    Filed: January 31, 2008
    Publication date: September 11, 2008
    Applicants: WYETH, The Government USA, as respresented by the Secretary, Department of Health
    Inventors: Michael Chapman Byrne, Ethan Menahem Shevach, Mary Collins, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young
  • CD25markers and uses thereof
    Publication number: 20030133936
    Abstract: The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25+ differential markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an autoimmune disorder or transplant rejection. Methods for determining the long term prognosis in a subject are also provided.
    Type: Application
    Filed: July 12, 2002
    Publication date: July 17, 2003
    Inventors: Michael Chapman Byrne, Ethan Menahem Shevach, Mary Collins, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young